ZEPP HEALTH CORP-ADR (ZEPP) Fundamental Analysis & Valuation

NYSE:ZEPP • US98945L2043

19.63 USD
+1.01 (+5.42%)
At close: Mar 4, 2026
19.63 USD
0 (0%)
After Hours: 3/4/2026, 7:02:13 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ZEPP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall ZEPP gets a fundamental rating of 2 out of 10. We evaluated ZEPP against 124 industry peers in the Electronic Equipment, Instruments & Components industry. ZEPP may be in some trouble as it scores bad on both profitability and health. ZEPP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. ZEPP Profitability Analysis

1.1 Basic Checks

  • In the past year ZEPP has reported negative net income.
  • The reported net income has been mixed in the past 5 years: ZEPP reported negative net income in multiple years.
  • In multiple years ZEPP reported negative operating cash flow during the last 5 years.
ZEPP Yearly Net Income VS EBIT VS OCF VS FCFZEPP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

  • ZEPP has a Return On Assets of -14.18%. This is in the lower half of the industry: ZEPP underperforms 66.13% of its industry peers.
  • ZEPP's Return On Equity of -34.61% is on the low side compared to the rest of the industry. ZEPP is outperformed by 73.39% of its industry peers.
Industry RankSector Rank
ROA -14.18%
ROE -34.61%
ROIC N/A
ROA(3y)-8.27%
ROA(5y)-3.78%
ROE(3y)-16.67%
ROE(5y)-7.49%
ROIC(3y)N/A
ROIC(5y)N/A
ZEPP Yearly ROA, ROE, ROICZEPP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 -30

1.3 Margins

  • ZEPP has a Gross Margin of 37.59%. This is in the better half of the industry: ZEPP outperforms 60.48% of its industry peers.
  • ZEPP's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ZEPP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.57%
GM growth 5Y8.78%
ZEPP Yearly Profit, Operating, Gross MarginsZEPP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ZEPP Health Analysis

2.1 Basic Checks

  • ZEPP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ZEPP has less shares outstanding
  • ZEPP has less shares outstanding than it did 5 years ago.
  • ZEPP has a worse debt/assets ratio than last year.
ZEPP Yearly Shares OutstandingZEPP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ZEPP Yearly Total Debt VS Total AssetsZEPP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • ZEPP has an Altman-Z score of 2.21. This is not the best score and indicates that ZEPP is in the grey zone with still only limited risk for bankruptcy at the moment.
  • ZEPP has a Altman-Z score of 2.21. This is comparable to the rest of the industry: ZEPP outperforms 42.74% of its industry peers.
  • ZEPP has a Debt/Equity ratio of 0.85. This is a neutral value indicating ZEPP is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.85, ZEPP is doing worse than 85.48% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Altman-Z 2.21
ROIC/WACCN/A
WACC6.44%
ZEPP Yearly LT Debt VS Equity VS FCFZEPP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.10 indicates that ZEPP should not have too much problems paying its short term obligations.
  • ZEPP has a worse Current ratio (1.10) than 87.10% of its industry peers.
  • ZEPP has a Quick Ratio of 1.10. This is a bad value and indicates that ZEPP is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ZEPP has a Quick ratio of 0.77. This is amonst the worse of the industry: ZEPP underperforms 86.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.1
Quick Ratio 0.77
ZEPP Yearly Current Assets VS Current LiabilitesZEPP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. ZEPP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 23.53% over the past year.
  • Looking at the last year, ZEPP shows a very negative growth in Revenue. The Revenue has decreased by -42.69% in the last year.
  • The Revenue has been decreasing by -8.53% on average over the past years.
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.29%
Revenue 1Y (TTM)-42.69%
Revenue growth 3Y-27.67%
Revenue growth 5Y-8.53%
Sales Q2Q%-75.35%

3.2 Future

  • ZEPP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.28% yearly.
  • ZEPP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.24% yearly.
EPS Next Y85.63%
EPS Next 2Y38.52%
EPS Next 3Y25.28%
EPS Next 5YN/A
Revenue Next Year-49.23%
Revenue Next 2Y-16.57%
Revenue Next 3Y-4.24%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ZEPP Yearly Revenue VS EstimatesZEPP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
ZEPP Yearly EPS VS EstimatesZEPP Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 10 -10 20 30

More info and screens

Find the best growth stocksShow best growing peers

1

4. ZEPP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ZEPP. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZEPP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZEPP Price Earnings VS Forward Price EarningsZEPP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZEPP Per share dataZEPP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • ZEPP's earnings are expected to grow with 25.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.52%
EPS Next 3Y25.28%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ZEPP Dividend Analysis

5.1 Amount

  • ZEPP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZEPP Fundamentals: All Metrics, Ratios and Statistics

ZEPP HEALTH CORP-ADR

NYSE:ZEPP (3/4/2026, 7:02:13 PM)

After market: 19.63 0 (0%)

19.63

+1.01 (+5.42%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)11-04
Earnings (Next)03-24
Inst Owners48.68%
Inst Owner Change20.33%
Ins Owners5.91%
Ins Owner ChangeN/A
Market Cap1.18B
Revenue(TTM)352.86M
Net Income(TTM)-77.87M
Analysts85
Price Target63.07 (221.29%)
Short Float %4.98%
Short Ratio2.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.89
P/FCF N/A
P/OCF N/A
P/B 5.23
P/tB 5.85
EV/EBITDA N/A
EPS(TTM)-2.96
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS3.33
BVpS3.75
TBVpS3.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.18%
ROE -34.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.59%
FCFM N/A
ROA(3y)-8.27%
ROA(5y)-3.78%
ROE(3y)-16.67%
ROE(5y)-7.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.57%
GM growth 5Y8.78%
F-ScoreN/A
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.1
Quick Ratio 0.77
Altman-Z 2.21
F-ScoreN/A
WACC6.44%
ROIC/WACCN/A
Cap/Depr(3y)22.81%
Cap/Depr(5y)96.65%
Cap/Sales(3y)0.51%
Cap/Sales(5y)0.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.29%
EPS Next Y85.63%
EPS Next 2Y38.52%
EPS Next 3Y25.28%
EPS Next 5YN/A
Revenue 1Y (TTM)-42.69%
Revenue growth 3Y-27.67%
Revenue growth 5Y-8.53%
Sales Q2Q%-75.35%
Revenue Next Year-49.23%
Revenue Next 2Y-16.57%
Revenue Next 3Y-4.24%
Revenue Next 5YN/A
EBIT growth 1Y-91.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-162.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-156.9%
OCF growth 3YN/A
OCF growth 5YN/A

ZEPP HEALTH CORP-ADR / ZEPP FAQ

What is the fundamental rating for ZEPP stock?

ChartMill assigns a fundamental rating of 2 / 10 to ZEPP.


What is the valuation status for ZEPP stock?

ChartMill assigns a valuation rating of 1 / 10 to ZEPP HEALTH CORP-ADR (ZEPP). This can be considered as Overvalued.


Can you provide the profitability details for ZEPP HEALTH CORP-ADR?

ZEPP HEALTH CORP-ADR (ZEPP) has a profitability rating of 2 / 10.


What is the expected EPS growth for ZEPP HEALTH CORP-ADR (ZEPP) stock?

The Earnings per Share (EPS) of ZEPP HEALTH CORP-ADR (ZEPP) is expected to grow by 85.63% in the next year.